Zimmer Biomet HoldingsXSWX:ZBH +2.80%72 5-Year Yield-on-Cost % is 1.05 as of Jul. 11, 2026, which is 28% above its 10-year median of 0.82. GuruFocus rates XSWX:ZBH with a GF Score™ of 72/100 and a GF Value™ of CHF101.61. The stock has 3 warning signs investors should review. Among 327 Medical Devices & Instruments companies, Zimmer Biomet Holdings ranks worse than 71.87% on this metric.
Zimmer Biomet Holdings's yield on cost for the quarter that ended in Mar. 2026 was 1.05.
The historical rank and industry rank for Zimmer Biomet Holdings's 5-Year Yield-on-Cost % or its related term are showing as below:
XSWX:ZBH'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.56 Med: 0.82 Max: 1.17
Current: 1.05
During the past 13 years, Zimmer Biomet Holdings's highest Yield on Cost was 1.17. The lowest was 0.56. And the median was 0.82.
XSWX:ZBH's 5-Year Yield-on-Cost % is ranked worse than 71.87% of 327
companies
in the Medical Devices & Instruments industry
Industry Median: 2.34
vs XSWX:ZBH: 1.05
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Zimmer Biomet Holdings 5-Year Yield-on-Cost % Related Terms
XSWX:ZBH vs STE, PEN, GMED: 5-Year Yield-on-Cost % Comparison
For the Medical Devices subindustry, Zimmer Biomet Holdings's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zimmer Biomet Holdings 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Zimmer Biomet Holdings's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Zimmer Biomet Holdings's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Zimmer Biomet Holdings (XSWX:ZBH) has a 5-Year Yield-on-Cost % of 1.05 as of Jul. 11, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Zimmer Biomet Holdings and its competitors. This is 28% above median its historical median of 0.82. Over the past decade, Zimmer Biomet Holdings' 5-Year Yield-on-Cost % has ranged from 0.56 to 1.17. According to the industry distribution chart, Zimmer Biomet Holdings ranks #235 out of 327 companies in the Medical Devices & Instruments industry, placing it in the top 71.9%.
Is Zimmer Biomet Holdings' 5-Year Yield-on-Cost % too high?
Zimmer Biomet Holdings' current 5-Year Yield-on-Cost % of 1.05 is 28% above median its 10-year median of 0.82. Over the past 10 years, this metric has ranged from a low of 0.56 to a high of 1.17. The Medical Devices & Instruments industry median 5-Year Yield-on-Cost % is 2.34. Zimmer Biomet Holdings' value of 1.05 is 55.1% below this industry median. Based on the distribution chart, Zimmer Biomet Holdings ranks #235 out of 327 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Zimmer Biomet Holdings has a GF Score™ of 72/100, reflecting its overall financial health beyond just this single metric.
How does Zimmer Biomet Holdings' 5-Year Yield-on-Cost % compare to STE and PEN?
According to the Medical Devices & Instruments industry distribution chart, Zimmer Biomet Holdings ranks #235 out of 327 companies for 5-Year Yield-on-Cost %. This places Zimmer Biomet Holdings in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.34. Zimmer Biomet Holdings' value of 1.05 is 55.1% below this benchmark. Historically, Zimmer Biomet Holdings' own 5-Year Yield-on-Cost % has ranged from 0.56 to 1.17 over the past decade. While the company's 10-year median is 0.82 vs. the industry median of 2.34, Zimmer Biomet Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.34, based on 327 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zimmer Biomet Holdings's current 5-Year Yield-on-Cost % of 1.05 is 55.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Zimmer Biomet Holdings and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zimmer Biomet Holdings's current 5-Year Yield-on-Cost % is 1.05, which is 28% above median its own 10-year median of 0.82. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zimmer Biomet Holdings stock overvalued right now?
Zimmer Biomet Holdings (XSWX:ZBH) has a current 5-Year Yield-on-Cost % of 1.05. The stock's GF Value™ is CHF101.61, compared to a current price of CHF73.50 — trading 27.7% below its estimated fair value. The current 5-Year Yield-on-Cost % is 1.05, which is 28% above median its 10-year median of 0.82 and 55.1% below the Medical Devices & Instruments industry median of 2.34. Zimmer Biomet Holdings' overall GF Score™ is 72/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Zimmer Biomet Holdings (XSWX:ZBH), the current 5-Year Yield-on-Cost % is 1.05 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zimmer Biomet Holdings (XSWX:ZBH) Overvalued in 2026?
Based on GuruFocus' analysis, Zimmer Biomet Holdings stock appears to be undervalued.
The current stock price of CHF73.50 is trading 27.7% below its estimated GF Value™ of CHF101.61.
Key valuation signals for XSWX:ZBH:
5-Year Yield-on-Cost %: 1.05 (28% above median its 10-year median of 0.82)
GF Value™: CHF101.61 vs. price of CHF73.50 (27.7% below fair value)
Industry Position: 55.1% below the Medical Devices & Instruments median (#235 of 327)
No single metric tells the full story. See the XSWX:ZBH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
72GF Score
Get the complete analysis for XSWX:ZBH
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ZBH has been successfully added to your 